In summary, our results indicate that MCP-1 levels in CSF cannot distinguish between PD, MSA, and controls, but correlate with disease progression in the PD group, suggesting its usefulness as part of a bigger panel to predict motor dysfunction in PD. This evidence concerns the gene CCL2 and Parkinson disease.